drugset / Trial / NCT01212588

Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)

NCT01212588

Phase 2 Terminated 22 enrolled Indiana University
RandomizedParallel-groupTriple-blindTreatment

Summary

Participants will be randomized to either Mifepristone 600mg once daily for seven days or Placebo tablet once daily for seven days. Rating scales, vital signs, cortisol levels will be collected for evaluation.

Timeline

Start
2010-09
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Mifepristone Small molecule 600 mg